0.7301

1.07% -0.0079

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $0.7301, with a volume of 59,679. It is down -1.07% in the last 24 hours and down -2.52% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$0.738

Open:

$0.73

24h Volume:

59,679

Relative Volume:

0.39

Market Cap:

$28.49M

Revenue:

$135.87M

Net Income/Loss:

$72.20M

P/E Ratio:

0.5142

EPS:

1.42

Net Cash Flow:

$45.09M

1W Performance:

+0.70%

1M Performance:

-2.52%

6M Performance:

-31.77%

1Y Performance:

-64.98%

1-Day Range:

$0.73

$0.7439

1-Week Range:

$0.701

$0.7439

52-Week Range:

$0.66

$2.21

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1164)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2024-11-11

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	0.7301	28.80M	135.87M	72.20M	45.09M	1.42
ZTS Zoetis Inc	152.12	68.04B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.48	46.30B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.88	44.25B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.54	18.73B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	304.50	13.82B	2.99B	1.21B	1.13B	25.06

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Jul 24, 2025

Is SCYNEXIS Inc. a good long term investmentTremendous growth opportunities - Autocar Professional

Jul 24, 2025

What drives SCYNEXIS Inc. stock priceFastest return on investment - Autocar Professional

Jul 24, 2025

Jul 23, 2025

What analysts say about SCYNEXIS Inc. stockUnstoppable profit momentum - Autocar Professional

Jul 23, 2025

SCYNEXIS Inc. Stock Analysis and ForecastFast-track wealth growth - Autocar Professional

Jul 23, 2025

Jul 19, 2025

Is ATH.PRA a good long term investmentSkyrocketing returns - Jammu Links News

Jul 19, 2025

Jul 16, 2025

What makes SCYNEXIS Inc. stock price move sharplyTop Analyst Picks - Newser

Jul 16, 2025

Jul 15, 2025

Why SCYNEXIS Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser

Jul 15, 2025

How SCYNEXIS Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser

Jul 15, 2025